Improvement in the clinical manifestations of interstitial lung disease following treatment with placental mesenchymal stromal cell extracellular vesicles in a patient with systemic sclerosis: A case report.
Extracellular vesicles
Interstitial lung disease
Mesenchymal stromal cells
Systemic sclerosis
Journal
Respiratory medicine case reports
ISSN: 2213-0071
Titre abrégé: Respir Med Case Rep
Pays: England
ID NLM: 101604463
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
08
2023
revised:
17
09
2023
accepted:
30
09
2023
medline:
6
11
2023
pubmed:
6
11
2023
entrez:
6
11
2023
Statut:
epublish
Résumé
Interstitial lung disease (ILD) is a severe systemic sclerosis (SSc) complication with no current approved or golden standard treatment. This report aims to investigate the effectiveness of treatment with placental mesenchymal stromal cell (MSC) extracellular vesicles (EVs) in a patient with ILD due to SSc. The patient was a 55-year-old woman with a ten years history of SSc complicated by severe ILD. Over time, her lung disease progressed to interstitial fibrosis despite being treated with mycophenolate mofetil and monthly pulses of cyclophosphamide. Thus, she was treated with eight doses of placenta MSC-EVs. Four weeks after the third dose (Day 31 after the first dose), she reported marked improvement in her clinical symptoms, such as dyspnea and cough. Also, chest computed tomography (CT) scans demonstrated a significant reduction in ground glass consolidations and fibrotic changes. The patient was subsequently followed for twelve months, with findings showing significant improvement in exercise tolerance and reduced supplemental oxygen need. In this single case, placental MSC-EVs were seen to provide a potentially efficient treatment for SSc-related ILD; however, further investigation and clinical trials are necessary.
Sections du résumé
Background
UNASSIGNED
Interstitial lung disease (ILD) is a severe systemic sclerosis (SSc) complication with no current approved or golden standard treatment. This report aims to investigate the effectiveness of treatment with placental mesenchymal stromal cell (MSC) extracellular vesicles (EVs) in a patient with ILD due to SSc.
Case presentation
UNASSIGNED
The patient was a 55-year-old woman with a ten years history of SSc complicated by severe ILD. Over time, her lung disease progressed to interstitial fibrosis despite being treated with mycophenolate mofetil and monthly pulses of cyclophosphamide. Thus, she was treated with eight doses of placenta MSC-EVs. Four weeks after the third dose (Day 31 after the first dose), she reported marked improvement in her clinical symptoms, such as dyspnea and cough. Also, chest computed tomography (CT) scans demonstrated a significant reduction in ground glass consolidations and fibrotic changes. The patient was subsequently followed for twelve months, with findings showing significant improvement in exercise tolerance and reduced supplemental oxygen need.
Conclusion
UNASSIGNED
In this single case, placental MSC-EVs were seen to provide a potentially efficient treatment for SSc-related ILD; however, further investigation and clinical trials are necessary.
Identifiants
pubmed: 37928415
doi: 10.1016/j.rmcr.2023.101923
pii: S2213-0071(23)00118-1
pmc: PMC10622869
doi:
Types de publication
Case Reports
Langues
eng
Pagination
101923Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Tissue Eng Regen Med. 2022 Feb;19(1):141-150
pubmed: 34784013
J Autoimmun. 2016 Jun;70:31-9
pubmed: 27052182
Autoimmun Rev. 2021 Dec;20(12):102978
pubmed: 34718159
J Autoimmun. 2021 Jul;121:102660
pubmed: 34020253
Int J Mol Sci. 2019 Sep 04;20(18):
pubmed: 31487964
Front Cell Dev Biol. 2021 Feb 15;9:600711
pubmed: 33659247
Rheum Dis Clin North Am. 2015 Aug;41(3):383-98
pubmed: 26210125
J Cell Mol Med. 2022 Jan;26(2):588-592
pubmed: 34873830
Oxid Med Cell Longev. 2019 Dec 16;2019:4506303
pubmed: 31949877
N Engl J Med. 2009 May 7;360(19):1989-2003
pubmed: 19420368
Ann Rheum Dis. 2001 Jun;60(6):577-84
pubmed: 11350846